- Tezosentan
Drugbox
IUPAC_name = "N"- [6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2- [2-(2"H"-tetrazol-5-yl)pyridin-4-yl] pyrimidin-4-yl] -5-propan-2-ylpyridine-2-sulfonamide
CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem = 151174
DrugBank =
chemical_formula =
C=27 | H=27 | N=9 | O=6 | S=1
molecular_weight = 605.624
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Tezosentan is a non-selective ETA and ETB receptor antagonist. cite journal |last=Urbanowicz |first=W |authorlink= |coauthors=Sogni, P, Moreau, R, Tazi, K A, Barriere, E, Poirel, O, Martin, A, Guimont, M C, Cazals-Hatem, D, Lebrec, D |year=2004 |month= |title=Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats |journal=Gut |volume=53 |issue= |pages=1844–1849 |id= |url=http://gut.bmj.com/cgi/content/abstract/53/12/1844 |accessdate= |quote= publisher= BMJ Publishing Group Ltd & British Society of Gastroenterology|doi=10.1136/gut.2003.036517 |pmid=15542526] It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.cite web |url=http://www.news-medical.net/?id=32315 |title=Tezosentan does not appear to improve symptoms for patients with acute heart failure |accessdate=2007-11-24 |author= |date= 7-Nov-2007 |work= Medical Studies/Trials |publisher=news-medical.net ]
References
Wikimedia Foundation. 2010.
